What is the role of iFOBT in screening for colorectal cancer?

Gut

Volumn 56, Issue 10, 2007, Pages 1343-1344

  Ransohoff, David F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNOCHEMCIAL BASED FECAL OCCULT BLOOD TEST; METHODOLOGY; OCCULT BLOOD TEST; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SHORT SURVEY;

COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 34948813475     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.124107     Document Type: Short Survey

References (16)

1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
2. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
3. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
4. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003;124:544-60.
5. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002;137:129-31.
6. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society Guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 2001;51:38-75.
7. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
8. Fraser CG, Mathew CM, Mowat NAG, et al. Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach. Gut 2007;56:1415-8.
9. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-7.
10. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
11. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
12. Pignone M, Russell L, Wagner J. Economic models of colorectal cancer screening in average-risk adults: workshop summary http://www.nap.edu/ catalog/11228.html, Washington, DC: National Academies Press 2005.
13. Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology 2005;128:1685-95.
14. Allison JE. Colon cancer screening guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005;129:745-8.
15. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.
16. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.